The vaccine’s efficacy data meets its expectations for emergency use authorisation, the FDA finds in a new report. Pfizer cleared the next hurdle in the race to get its COVID-19 vaccine approved for emergency use in the United States on Tuesday after
A billionaire scientist behind Pfizer and BioNTech’s breakthrough COVID-19 vaccine says he expects it to “bash the virus over the head” and ultimately end the pandemic, according to a report. Following an announcement this week that the vaccine was more than 90 percent
Health Secretary Matt Hancock recently hailed the news that Pfizer’s vaccine was 90 percent effective in developing an immune response to coronavirus. Both Oxford and Pfizer’s candidates are in phase three clinical trials, and are expected to be released to the most